New Brunswick: American multinational company Johnson & Johnson in an official statement said a single dose of its Covid-19 vaccine offers strong protection against the delta variant of the coronavirus, on Thursday. It added that the protection could last for at least eight months.
A Single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the statement read.
“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, MD, PhD, Global Head, Janssen Research & Development, Johnson & Johnson.
The analysis was made after blood samples were obtained from the participants of the study. The data showed that the Johnson & Johnson single-shot COVID-19 vaccine-elicited neutralizing antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa where high efficacy against severe or critical disease was demonstrated.
The study also added that Johnson & Johnson’s single-dose COVID-19 vaccine was 85 percent effective against severe or critical disease. The vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta (P.2) variants during the study period.
According to the statement, J&J vaccine received Emergency Use Authorization (EUA) in the United States on February 27 and Conditional Marketing Authorization (CMA) by the European Commission on March 11, 2021.
The World Health Organization (WHO) gave Johnson & Johnson vaccine nod for Emergency Use Listing on March 12, 2021. The company is for regulatory approval in many more countries as well.